NASDAQ:BPMC Blueprint Medicines (BPMC) Stock Price, News & Analysis → Bible Shocker: Have You Seen Elon Musk’s Miracle? (From InvestorPlace) (Ad) Free BPMC Stock Alerts $104.96 -1.68 (-1.58%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$103.23▼$107.1750-Day Range$85.18▼$108.7852-Week Range$43.89▼$111.02Volume415,572 shsAverage Volume732,004 shsMarket Capitalization$6.57 billionP/E RatioN/ADividend YieldN/APrice Target$102.65 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Blueprint Medicines alerts: Email Address Blueprint Medicines MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.53 Rating ScoreUpside/Downside2.2% Downside$102.65 Price TargetShort InterestBearish7.25% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.63Based on 17 Articles This WeekInsider TradingSelling Shares$9.55 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($5.15) to ($2.07) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.68 out of 5 starsMedical Sector857th out of 921 stocksPharmaceutical Preparations Industry392nd out of 418 stocks 2.3 Analyst's Opinion Consensus RatingBlueprint Medicines has received a consensus rating of Moderate Buy. The company's average rating score is 2.53, and is based on 9 buy ratings, 5 hold ratings, and 2 sell ratings.Amount of Analyst CoverageBlueprint Medicines has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Blueprint Medicines' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.25% of the outstanding shares of Blueprint Medicines have been sold short.Short Interest Ratio / Days to CoverBlueprint Medicines has a short interest ratio ("days to cover") of 5.5.Change versus previous monthShort interest in Blueprint Medicines has recently increased by 6.82%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBlueprint Medicines does not currently pay a dividend.Dividend GrowthBlueprint Medicines does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BPMC. Previous Next 3.1 News and Social Media Coverage News SentimentBlueprint Medicines has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Blueprint Medicines this week, compared to 6 articles on an average week.Search InterestOnly 1 people have searched for BPMC on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows4 people have added Blueprint Medicines to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Blueprint Medicines insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,554,679.00 in company stock.Percentage Held by InsidersOnly 3.88% of the stock of Blueprint Medicines is held by insiders.Read more about Blueprint Medicines' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Blueprint Medicines are expected to grow in the coming year, from ($5.15) to ($2.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Blueprint Medicines is -21.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Blueprint Medicines is -21.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBlueprint Medicines has a P/B Ratio of 21.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Blueprint Medicines' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market InsidersThe CHIPS Act MotherlodeIf you haven’t heard yet, the CHIPS Act is the US government pouring $280 BILLION into the manufacturing of US semiconductors. A lot of companies will make a fortune from this.Click here to see my #1 investment for 2024. About Blueprint Medicines Stock (NASDAQ:BPMC)Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.Read More BPMC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BPMC Stock News HeadlinesMay 7, 2024 | insidertrades.comAriel Hurley Sells 1,834 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) StockMay 7, 2024 | insidertrades.comMichael Landsittel Sells 10,000 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) StockMay 18 at 5:32 AM | americanbankingnews.comBlueprint Medicines Co. (NASDAQ:BPMC) Short Interest Up 6.8% in AprilMay 17 at 2:34 AM | americanbankingnews.comAnalysts Issue Forecasts for Blueprint Medicines Co.'s Q2 2024 Earnings (NASDAQ:BPMC)May 15, 2024 | msn.comStephens & Co. Initiates Coverage of Blueprint Medicines (BPMC) with Overweight RecommendationMay 15, 2024 | americanbankingnews.comBlueprint Medicines (NASDAQ:BPMC) Receives New Coverage from Analysts at StephensMay 14, 2024 | msn.comBlueprint Medicines started at buy by Stephens, citing Ayvakit franchiseMay 14, 2024 | markets.businessinsider.comUnveiling 18 Analyst Insights On Blueprint MedicinesMay 9, 2024 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on Blueprint Medicines (BPMC)May 9, 2024 | americanbankingnews.comQ2 2024 Earnings Estimate for Blueprint Medicines Co. Issued By Leerink Partnrs (NASDAQ:BPMC)May 7, 2024 | finance.yahoo.comZacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and LigandMay 7, 2024 | msn.comLeerink Partners Upgrades Blueprint Medicines (BPMC)May 6, 2024 | prnewswire.comBlueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 4, 2024 | markets.businessinsider.comSell/High Risk: Cautious Outlook on Blueprint Medicines Amidst Unsustainable Growth FactorsMay 4, 2024 | finance.yahoo.comBlueprint Medicines Corp (BPMC) (Q1 2024) Earnings Call Transcript Highlights: Surpassing ...May 4, 2024 | markets.businessinsider.comBuy Rating Affirmed for Blueprint Medicines on Strong Financials and Clinical Pipeline ProspectsMay 4, 2024 | finance.yahoo.comBlueprint Medicines Corporation (NASDAQ:BPMC) Q1 2024 Earnings Call TranscriptMay 3, 2024 | finance.yahoo.comQ1 2024 Blueprint Medicines Corp Earnings CallMay 2, 2024 | marketwatch.comBlueprint Medicines Shares Hit 52-Week on Strong Ayvakit SalesMay 2, 2024 | msn.comBPMC Stock Earnings: Blueprint Medicines Beats EPS, Beats Revenue for Q1 2024May 2, 2024 | finance.yahoo.comBlueprint Medicines Corp Reports Q1 2024 Earnings, Surpasses Revenue Estimates and Raises ...May 2, 2024 | seekingalpha.comBlueprint Medicines Corporation 2024 Q1 - Results - Earnings Call PresentationMay 2, 2024 | prnewswire.comBlueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue GuidanceApril 29, 2024 | seekingalpha.comRigel Pharmaceuticals: No Respect With Little Justification, Worth Considering A BuyApril 26, 2024 | finance.yahoo.comRubrik to debut on NYSE, IPO priced at $32 per shareSee More Headlines Receive BPMC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Blueprint Medicines and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/15/2024Today5/18/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BPMC CUSIPN/A CIK1597264 Webwww.blueprintmedicines.com Phone(617) 374-7580FaxN/AEmployees655Year Founded2011Price Target and Rating Average Stock Price Target$102.65 High Stock Price Target$168.00 Low Stock Price Target$43.00 Potential Upside/Downside-2.2%Consensus RatingModerate Buy Rating Score (0-4)2.53 Research Coverage17 Analysts Profitability EPS (Most Recent Fiscal Year)($4.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-506,980,000.00 Net Margins-102.15% Pretax Margin-101.93% Return on Equity-193.48% Return on Assets-42.98% Debt Debt-to-Equity Ratio0.67 Current Ratio3.76 Quick Ratio3.61 Sales & Book Value Annual Sales$249.38 million Price / Sales26.36 Cash FlowN/A Price / Cash FlowN/A Book Value$4.96 per share Price / Book21.16Miscellaneous Outstanding Shares62,620,000Free Float58,825,000Market Cap$6.57 billion OptionableOptionable Beta0.65 Social Links 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMs. Kathryn Haviland (Age 48)President, CEO & Director Comp: $1.17MMr. Alexis A. Borisy A.M. (Age 52)Co-Founder & Director Comp: $50kMr. Michael Landsittel (Age 52)Chief Financial Officer Comp: $785.36kMs. Tracey L. McCain Esq. (Age 56)Executive VP, Chief Legal & Compliance Officer and Secretary Comp: $764.9kDr. Fouad Namouni M.D. (Age 55)President of Research & Development Comp: $916.4kMs. Ariel Hurley (Age 50)Senior VP, Finance & Principal Accounting Officer Dr. Christopher K. Murray Ph.D. (Age 60)Senior VP of Technical Operations and Chief Technical Operations & Quality Officer Comp: $338.37kDr. Percy H. Carter M.B.A. (Age 53)Ph.D., Chief Scientific Officer Comp: $761.15kJenna CohenSenior Director & Head of Investor RelationsMs. Debra Durso-Bumpus (Age 54)Chief People Officer More ExecutivesKey CompetitorsCytokineticsNASDAQ:CYTKIntra-Cellular TherapiesNASDAQ:ITCIJazz PharmaceuticalsNASDAQ:JAZZAscendis Pharma A/SNASDAQ:ASNDIonis PharmaceuticalsNASDAQ:IONSView All CompetitorsInsiders & InstitutionsComerica BankBought 10,435 shares on 5/17/2024Ownership: 0.018%Walleye Trading LLCSold 2,800 shares on 5/17/2024Ownership: 0.000%Jane Street Group LLCBought 8,700 shares on 5/16/2024Ownership: 0.000%California State Teachers Retirement SystemSold 3,316 shares on 5/16/2024Ownership: 0.095%Kennedy Capital Management LLCBought 2,320 shares on 5/16/2024Ownership: 0.004%View All Insider TransactionsView All Institutional Transactions BPMC Stock Analysis - Frequently Asked Questions Should I buy or sell Blueprint Medicines stock right now? 17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Blueprint Medicines in the last twelve months. There are currently 2 sell ratings, 5 hold ratings, 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BPMC shares. View BPMC analyst ratings or view top-rated stocks. What is Blueprint Medicines' stock price target for 2024? 17 brokerages have issued 12 month target prices for Blueprint Medicines' stock. Their BPMC share price targets range from $43.00 to $168.00. On average, they expect the company's stock price to reach $102.65 in the next year. This suggests that the stock has a possible downside of 2.2%. View analysts price targets for BPMC or view top-rated stocks among Wall Street analysts. How have BPMC shares performed in 2024? Blueprint Medicines' stock was trading at $92.24 on January 1st, 2024. Since then, BPMC shares have increased by 13.8% and is now trading at $104.96. View the best growth stocks for 2024 here. When is Blueprint Medicines' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024. View our BPMC earnings forecast. How were Blueprint Medicines' earnings last quarter? Blueprint Medicines Co. (NASDAQ:BPMC) announced its earnings results on Thursday, February, 15th. The biotechnology company reported ($1.82) EPS for the quarter, beating the consensus estimate of ($2.04) by $0.22. The biotechnology company had revenue of $71.96 million for the quarter, compared to analysts' expectations of $67.34 million. Blueprint Medicines had a negative trailing twelve-month return on equity of 193.48% and a negative net margin of 102.15%. The firm's quarterly revenue was up 85.5% on a year-over-year basis. During the same period in the prior year, the firm earned ($2.65) EPS. What ETFs hold Blueprint Medicines' stock? ETFs with the largest weight of Blueprint Medicines (NASDAQ:BPMC) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE), Tema Oncology ETF (CANC), WisdomTree BioRevolution Fund (WDNA), Harbor Corporate Culture Small Cap ETF (HAPS), Virtus LifeSci Biotech Products ETF (BBP), BlackRock Future Health ETF (BMED), iShares Genomics Immunology and Healthcare ETF (IDNA) and Range Cancer Therapeutics ETF (CNCR). What is Kate Haviland's approval rating as Blueprint Medicines' CEO? 16 employees have rated Blueprint Medicines Chief Executive Officer Kate Haviland on Glassdoor.com. Kate Haviland has an approval rating of 100% among the company's employees. This puts Kate Haviland in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 93.0% of employees surveyed would recommend working at Blueprint Medicines to a friend. What other stocks do shareholders of Blueprint Medicines own? Based on aggregate information from My MarketBeat watchlists, some companies that other Blueprint Medicines investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Pfizer (PFE), Gilead Sciences (GILD), QUALCOMM (QCOM), Amarin (AMRN), CRISPR Therapeutics (CRSP) and Nektar Therapeutics (NKTR). When did Blueprint Medicines IPO? Blueprint Medicines (BPMC) raised $115 million in an initial public offering (IPO) on Thursday, April 30th 2015. The company issued 7,200,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Cowen and Company served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. Who are Blueprint Medicines' major shareholders? Blueprint Medicines' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (10.31%), Price T Rowe Associates Inc. MD (10.21%), William Blair Investment Management LLC (2.79%), Lord Abbett & CO. LLC (2.15%), Hood River Capital Management LLC (0.77%) and Jane Street Group LLC (0.00%). Insiders that own company stock include Ariel Hurley, Christina Rossi, Christopher K Murray, Debra Durso-Bumpus, Fouad Namouni, George Demetri, Jeffrey W Albers, Kate Haviland, L Becker Hewes, Mark Alan Goldberg, Michael Landsittel, Percy H Carter and Tracey L Mccain. View institutional ownership trends. How do I buy shares of Blueprint Medicines? Shares of BPMC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BPMC) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsDems have chosen Biden replacement?Paradigm PressThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersBuy this small stock before coming AI Tidal WaveChaikin AnalyticsUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Blueprint Medicines Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.